Sartorius completed the acquisition of Polyplus from Warburg Pincus for €2.6bn.

Sartorius, a biotechnology company, completed the acquisition of Polyplus, an upstream solutions provider for advanced biologic and cell and gene therapy, from Warburg Pincus, a global growth investor, for €2.6bn. “This contemplated acquisition is a major milestone in the history of Polyplus, and a recognition of its innovative upstream market leadership position and our highly talented Polyplus teams around the world. We would be excited to join forces with a world class bioprocess market leader as Sartorius. Our combined portfolios would create a unique ability to optimize the total process workflow to deliver unparalleled value for cell/gene and DNA/RNA therapy customers, in a strong effort to make these critical needed therapies more affordable," Mario Philips, Polyplus CEO.